Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

Basilea Pharmaceutica (SIX: BSLN) secures additional $5.4m BARDA antibiotic funding >

Jyoti Prakash, CFA | Healthcare | Comment | 1 day ago

Amplia Therapeutics (ASX: ATX) – Eli Lilly collaboration expands narmafotinib into lung cancer >

Arron Aatkar, PhD | Healthcare | Comment | 2 days ago

QBiotics reports positive head and neck cancer data >

Arron Aatkar, PhD | Healthcare | Comment | 3 days ago

SEE ALL COMMENTARY >

Actinogen Medical (ACW)

Latest price

AUD0.04

— 0.00 (−2.33)

As at 05/08/2026

Market capitalisation: AUD160m

Equities

Equities by Sector

Sectors

Megatrends

Thematics

Latest

Edison explains: Europe’s ageing buildings

Stock of the month – PZ Cussons

Q226 reflections: Leadership swings back – the value case holds

Audiovisual

Latest

The Metals Company – equity proposition

Vantage: Rockwood Strategic – UK small-cap value and active engagement

Bull, Bear & Beyond – Living REIT: executive interview

About Edison

Corporates

Investors

Careers

Healthcare Equities

Actinogen Medical (ACW)

AUD0.04

Actinogen Medical — Approaching an inflection point for Xanamem

Actinogen Medical — XanaMIA passes interim analysis and marches on

Actinogen Medical — XanaMIA passes first safety milestone

See morecontent on

AFT Pharmaceuticals (AFT)

NZD4.75

AFT Pharmaceuticals — Making progress on growth strategy

AFT Pharmaceuticals — Setting the stage for sustained long-term growth

AFT Pharmaceuticals — Softer H1 on one-offs; recovery expected in H2

See morecontent on

Allergy Therapeutics (AGY)

GBP0.05

Allergy Therapeutics — H126 results reflect solid progress

See morecontent on

Alzinova (ALZ)

SEK1.03

Webinar: The CNS renaissance Biotech companies at the forefront

Alzinova — Innovative new approach to Alzheimer's

See morecontent on

AOTI (AOTI)

GBP0.98

Argent Biopharma (RGT)

AUD0.04

Argent Biopharma — Valuation report

Argent Biopharma — An innovative approach to drug development

MGC Pharmaceuticals — Rapid prescription growth in Australia and the UK

See morecontent on

Basilea Pharmaceutica (BSLN)

CHF50.70

Basilea Pharmaceutica – executive interview

Basilea Pharmaceutica — BAL2420 clinical entry expands antibiotic pipeline

Basilea Pharmaceutica — An emphatic start to 2026

See morecontent on

BioVersys (BIOV)

CHF26.00

BioVersys – executive interview

BioVersys — China data advances BV100’s global strategy

BioVersys — Phase III enrolment commences for BV100

See morecontent on

Cantargia (CANTA)

SEK1.80

Cantargia — Encouraging data for nadunolimab in CANFOUR

Cantargia — First patient treated in Phase II part of TRIFOUR

Cantargia — Next phase of clinical development in sight

See morecontent on

Cereno Scientific (CRNO-B)

SEK4.76

Cereno Scientific — A step closer to Phase IIb for CS014

Cereno Scientific — Strategic financing strengthens partnering position

Bull, Bear & Beyond – Cereno Scientific: executive interview

See morecontent on

Chosa (CHOSA)

SEK0.77

CHOSA Oncology – executive interview

Outlook for 2024: Life sciences – where has the conviction gone?

Chosa Oncology — Making headway in precision oncology

See morecontent on

Circio Holding (CRNA)

NOK8.23

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on